首页> 外文期刊>ClinicoEconomics and Outcomes Research >Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients
【24h】

Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients

机译:抗逆转录病毒药物治疗药物监测在感染人类免疫缺陷病毒的患者的常规临床管理中的影响以及相关的医疗保健费用:大量患者的真实生活研究

获取原文
           

摘要

Background: Highly active antiretroviral therapy (HAART) has reduced morbidity and mortality in patients infected with human immunodeficiency virus (HIV). Studies have documented high interindividual variability in the pharmacokinetics of antiretroviral drugs, which may impair the success of HAART if not managed properly. Therapeutic drug monitoring (TDM) is a useful diagnostic tool that helps clinicians to optimize drug doses so that drug concentrations associated with the highest therapeutic efficacy are obtained with a reduced risk of concentration-dependent adverse effects. The aim of this study was to assess whether use of TDM improves clinical outcomes and cost of illness. Methods: A retrospective cohort study was conducted at L Sacco University Hospital in Milan, Italy, in HIV-infected patients aged ≥18 years with at least one prescription of antiretroviral drugs for which TDM was applied. The inclusion period was from January 2010 to December 2011, with a follow-up period of up to 12 months. Laboratory and administrative databases were analyzed and matched with each other. Results: The cohort consisted of 5,347 patients (3,861 males and 1,486 females) of mean age 43.9±12.5 years. We found that TDM had been used in 143 of these patients, among whom adherence with therapy was significantly higher than among those in whom TDM had not been used (94% versus 78%). In TDM-controlled patients, the mean length of HIV-related hospitalization stay and mean cost of hospitalization were significantly reduced with respect to those observed in the group in which TDM had not been used (7.21 days versus 29.47 days and €293 versus €688, respectively). Conclusion: Inclusion of TDM as part of routine clinical optimization of drug dosing in HIV-infected patients is associated with higher adherence to therapy, reduced length of hospitalization stay, and reduced cost of illness.
机译:背景:高效抗逆转录病毒疗法(HAART)降低了感染人类免疫缺陷病毒(HIV)的患者的发病率和死亡率。研究表明,抗逆转录病毒药物的药代动力学存在很大的个体差异,如果管理不当,可能会损害HAART的成功。治疗性药物监测(TDM)是一种有用的诊断工具,可帮助临床医生优化药物剂量,从而获得具有最高治疗功效的药物浓度,并降低了浓度依赖性不良反应的风险。这项研究的目的是评估使用TDM是否可以改善临床结果和疾病成本。方法:在意大利米兰的萨科大学医院进行了一项回顾性队列研究,研究对象是年龄≥18岁且感染了HIV的患者,他们至少使用了一种抗逆转录病毒药物处方并应用了TDM。纳入期为2010年1月至2011年12月,随访期最长为12个月。分析了实验室和行政数据库并相互匹配。结果:该队列包括5347例患者(男3861例,女1486例),平均年龄43.9±12.5岁。我们发现,其中143例患者使用了TDM,其中对治疗的依从性显着高于未使用TDM的患者(94%比78%)。与未使用TDM的组相比,在TDM控制的患者中,与HIV相关的平均住院时间和平均住院费用显着降低(7.21天vs. 29.47天以及293欧元vs 688欧元) , 分别)。结论:将TDM作为HIV感染患者常规常规药物剂量优化的一部分与治疗依从性更高,住院时间缩短和疾病成本降低相关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号